Search

Your search keyword '"Chima, Margot"' showing total 21 results
Start Over Author "Chima, Margot"
21 results on '"Chima, Margot"'

4. Contributors

Author

Adams, David R., primary, Adams, Stewart, additional, Amin, Mina, additional, Avashia-Khemka, Nidhi, additional, Beck, Kristen M., additional, Bhatia, Bhavnit K., additional, Bhatia, Sravya Mallam, additional, Bhutani, Tina, additional, Braue, Jonathan A., additional, Brodell, Robert T., additional, Brodland, David G., additional, Broussard-Steinberg, Candace, additional, Callen, Jeffrey P., additional, Camisa, Charles, additional, Chehade, Ahmad, additional, Chima, Margot, additional, Clark, Richard A., additional, Cline, Abigail, additional, Cordoro, Kelly M., additional, Cruz Ramón, Julio C., additional, Davis, Loretta S., additional, Feld, Salma de la, additional, M.C. DeKlotz, Cynthia, additional, Duprat, Gabrielle-Eugenie, additional, Eaglstein, William H., additional, Elston, Carly A., additional, Elston, Dirk M., additional, Emerson, Ashley N., additional, Fabbro, Stephanie K., additional, Feldman, Steven R., additional, Ferris, Laura K., additional, Foley, Kelly A., additional, Forman, Seth B., additional, Garofola, Craig, additional, Gehlhausen, Jeffrey R., additional, Gelfand, Joel M., additional, Girardi, Michael, additional, Goerge, Tobias, additional, Gordon, Kenneth B., additional, Greiling, Teri M., additional, Grinich, Erin E., additional, Grove, Daniel, additional, Gupta, Aditya K., additional, Haggstrom, Anita, additional, Haley, Christopher T., additional, Hall, Russell P., additional, Hamzavi, Iltefat, additional, Heffernan, Michael P., additional, Helfrich, Yolanda R., additional, Hessel, Adam B., additional, Higgins, Shauna, additional, High, Whitney A., additional, Hrynewycz, Katherine, additional, Hsu, Sylvia, additional, Huether, Michael J., additional, Isaacs, Michael J., additional, Kaminer, Michael S., additional, Kandula, Prasanthi, additional, Kandula, Swetha, additional, Kang, Sewon, additional, Kapp, Marshall B., additional, Kim, Hee Jin, additional, Kim, Sa Rang, additional, Kingsley, Melanie, additional, Knowles, Sandra R., additional, Koo, John Y.M., additional, Kulp-Shorten, Carol L., additional, Landis, Megan N., additional, Lebwohl, Mark G., additional, Lee, Erica B., additional, Lee, Katherine B., additional, Lewis, Amy B., additional, Lim, Geoffrey F.S., additional, Lim, Henry W., additional, Lockshin, Benjamin N., additional, Luger, Thomas A., additional, Majerowski, Jacquelyn, additional, Mark, Lawrence A., additional, Marshall, Dana, additional, Martell, David, additional, Mays, Rachel R., additional, McElhiney, Linda F., additional, Mirowski, Ginat W., additional, Mori, Shoko, additional, Motaparthi, Kiran, additional, Mui, Uyen Ngoc, additional, Murray, Christian, additional, Nielson, Colton, additional, Noe, Megan H., additional, Okoye, Ginette A., additional, Owen, Cindy England, additional, Patton, Timothy, additional, Piette, Warren W., additional, Rahnama-Moghadam, Sahand, additional, Ramachandran, Sarika Manoj, additional, Rancour, Elizabeth A., additional, Rao, Jaggi, additional, Rosenbach, Misha, additional, Roy, Katherine, additional, Sachs, Dana L., additional, Sami, Naveed, additional, Sawaya, Marty E., additional, Schadt, Courtney R., additional, Schaffenburg, William, additional, Schlosser, Bethanee J., additional, Sekhon, Sahil, additional, Shah, Vidhi V., additional, Shapiro, Lori E., additional, Shear, Neil H., additional, Sheehan, Michael, additional, Simpson, Eric L., additional, Snodgrass, Alexandra, additional, Solish, Nowell, additional, Somani, Ally-Khan, additional, Somani, Najwa, additional, Strober, Bruce, additional, Sulk, Mathias, additional, Suozzi, Kathleen C., additional, Tharp, Michael D., additional, Tomayko, Mary M., additional, Tyring, Stephen K., additional, Vogt-Schiavo, Kaitlin, additional, Vuppalanchi, Raj, additional, Wang, Steve Q., additional, Weston, Gillian, additional, Wolverton, Stephen E., additional, Wu, Jashin J., additional, Wysong, Ashley, additional, Zic, John, additional, and Zwerner, Jeffrey P., additional

Published
2021
Full Text
View/download PDF

6. Distinct skin microbiome community structures in congenital ichthyosis

Author

Tham, Khek-Chian, primary, Lefferdink, Rachel, additional, Duan, Kaibo, additional, Lim, Seong Soo, additional, Wong, X.F. Colin C., additional, Ibler, Erin, additional, Wu, Benedict, additional, Abu-Zayed, Hajar, additional, Rangel, Stephanie M., additional, Del Duca, Ester, additional, Chowdhury, Mashkura, additional, Chima, Margot, additional, Kim, Hee Jee, additional, Lee, Bernett, additional, Guttman-Yassky, Emma, additional, Paller, Amy S., additional, and Common, John E. A., additional

Published
2022
Full Text
View/download PDF

7. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes

Author

Renert-Yuval, Yael, primary, Correa da Rosa, Joel, additional, Garcet, Sandra, additional, Pavel, Ana B., additional, Bares, Jennifer, additional, Chima, Margot, additional, Hawkes, Jason E., additional, Gilleaudeau, Patricia, additional, Sullivan-Whalen, Mary, additional, Singer, Giselle K., additional, Krueger, James G., additional, and Guttman-Yassky, Emma, additional

Published
2022
Full Text
View/download PDF

8. Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV–VI

Author

Kim, Hee J., primary, Del Duca, Ester, additional, Pavel, Ana B., additional, Singer, Giselle K., additional, Abittan, Brian J., additional, Chima, Margot A., additional, Kimmel, Grace, additional, Bares, Jennifer, additional, Baum, Danielle, additional, Gagliotti, Matthew, additional, Genece, Jordan, additional, Chu, Justin, additional, Lebwohl, Mark G., additional, and Guttman-Yassky, Emma, additional

Published
2022
Full Text
View/download PDF

9. Secukinumab responses vary across the spectrum of congenital ichthyosis in adults

Author

Lefferdink, Rachel, primary, Rangel, Stephanie M., additional, Chima, Margot, additional, Ibler, Erin, additional, Pavel, Ana B., additional, Kim, HeeJin, additional, Wu, Benedict, additional, Abu-Zayed, Hajar, additional, Wu, Jianni, additional, Jackson, Kathryn, additional, Singer, Giselle, additional, Choate, Keith A., additional, Guttman-Yassky, Emma, additional, and Paller, Amy S., additional

Published
2022
Full Text
View/download PDF

12. Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients

Author

Guttman‐Yassky, Emma, primary, Renert‐Yuval, Yael, additional, Bares, Jennifer, additional, Chima, Margot, additional, Hawkes, Jason E., additional, Gilleaudeau, Patricia, additional, Sullivan‐Whalen, Mary, additional, Singer, Giselle K., additional, Garcet, Sandra, additional, Pavel, Ana B., additional, Lebwohl, Mark G., additional, and Krueger, James G., additional

Published
2021
Full Text
View/download PDF

14. Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis

Author

Ungar, Benjamin, primary, Pavel, Ana B., additional, Li, Randall, additional, Kimmel, Grace, additional, Nia, John, additional, Hashim, Peter, additional, Kim, Hee Jin, additional, Chima, Margot, additional, Vekaria, Anjali S., additional, Estrada, Yeriel, additional, Xu, Hui, additional, Peng, Xiangyu, additional, Singer, Giselle K., additional, Baum, Danielle, additional, Mansouri, Yasaman, additional, Taliercio, Mark, additional, and Guttman-Yassky, Emma, additional

Published
2021
Full Text
View/download PDF

15. Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients.

Author

Guttman‐Yassky, Emma, Renert‐Yuval, Yael, Bares, Jennifer, Chima, Margot, Hawkes, Jason E., Gilleaudeau, Patricia, Sullivan‐Whalen, Mary, Singer, Giselle K., Garcet, Sandra, Pavel, Ana B., Lebwohl, Mark G., and Krueger, James G.

Subjects
ALOPECIA areata, DUPILUMAB, MONOCLONAL antibodies, CLINICAL trials, PATIENT selection, HAIR transplantation, HAIR removal
Abstract

Background: Treatments for alopecia areata (AA) patients with extensive scalp hair loss are limited, and recent evidence supports a role for type 2 T‐cell (Th2)‐immune response in AA. Dupilumab, a monoclonal antibody inhibiting Th2 signaling, approved for type 2 diseases including atopic dermatitis, was evaluated in AA patients. Methods: Alopecia areata patients with and without concomitant atopic dermatitis were randomized 2:1 to receive weekly subcutaneous dupilumab (300 mg) or placebo for 24 weeks, followed by another 24‐week dupilumab open‐label phase. The primary outcome was change from baseline in the Severity of Alopecia Tool (SALT) score at week 24; secondary outcomes included a range of measures of hair regrowth. Results: Forty and 20 patients were assigned to the dupilumab and placebo arms, respectively. At week 24, disease worsening was documented in the placebo arm, with a least‐squares mean change in the SALT score of −6.5 (95% confidence‐interval [CI], −10.4 to −2.6), versus a change of 2.2 (95% CI, −0.6 to 4.94) in the dupilumab arm (p <.05). After 48 weeks of dupilumab treatment, 32.5%, 22.5% and 15% of patients achieved SALT30/SALT50/SALT75 improvement, respectively, while in patients with baseline IgE ≥ 200 IU/ml response rates increased to 53.8%, 46.2%, and 38.5%, respectively. Moreover, baseline IgE predicts treatment response with 83% accuracy. No new safety signals were detected. Conclusions: This hypothesis‐driven trial is the first to indicate the possible pathogenic role of the Th2 axis and Th2 targeting in AA patients. Patient selection based on baseline serum IgE levels may improve treatment results (Clinicaltrials.gov number, NCT03359356). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial

Author

Hashim, Peter W., primary, Chima, Margot, additional, Kim, Hee J., additional, Bares, Jennifer, additional, Yao, Christopher J., additional, Singer, Giselle, additional, Chen, Tinley, additional, Genece, Jordan, additional, Baum, Danielle, additional, Kimmel, Grace W., additional, Nia, John K., additional, Gagliotti, Matthew, additional, and Lebwohl, Mark G., additional

Published
2020
Full Text
View/download PDF

21. Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab.

Author

Babalola F, Chima M, Jobarteh R, and Gottlieb A

Subjects
Antibodies, Monoclonal, Humans, Male, Middle Aged, Scalp pathology, Skin Diseases, Genetic, Cellulitis diagnosis, Cellulitis drug therapy, Scalp Dermatoses diagnosis, Scalp Dermatoses drug therapy
Abstract

Perifolliculitis capitis abscedens et suffodiens or dissecting cellulitis (DC) is a rare and chronic disease with a predilection for the occipital, vertex, and parietal scalp. DC is characterized by multinodular lesions with purulent drainage and sinus tract formation. It is classically seen in middle-aged males of African descent. The etiology of the disease is unknown; however, leading theories suggest that stasis associated with follicular occlusion begets bacterial infection and follicular destruction with a subsequent granulomatous and neutrophilic response.1 This is supported by the suppurative nature of the disease and its association with acne conglobota, pilonidal cysts, and hidradenitis suppurativa. These conditions are thought to have a shared etiology and are also widely accepted as being due to follicular occlusion.1 The approach to treatment of DC is varied as there is no current consensus on management. We present the case of risankizumab, an IL-23 inhibitor, used to successfully treat DC. J Drugs Dermatol. 2022;21(3): doi:10.36849/JDD.6699.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results